XCancer

Phase 1 First-in-Human (FIH), Dose Escalation and Dose Expansion Study of RYZ401, a Novel Radiopharmaceutical Therapy Labeled With Actinium-225 (225Ac), in Subjects With Neuroendocrine Tumors (NETs) and Other Selected Solid Tumors Expressing Somatostatin Receptors (SSTRs).

Description:

The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs.

Sponsor:

RayzeBio, Inc.

Phase:

Phase 1

Contacts:

RayzeBio Clinical Trials

clinicaltrials@rayzebio.com

+1 619 657 0057

Government Study Link:

NCT07165132 - Click here to see study on

ClinicalTrials.gov

RYZ401

Isotope(s):
Target(s):
  • SSTR2